Traditional Chinese medicine composition for preventing and treating yang deficiency and blood stasis fluid retention type chronic heart failure and application of traditional Chinese medicine composition

Abstract

The traditional Chinese medicine composition is prepared from the following components in parts by weight: 6 to 12 parts of herba epimedii, 10 to 30 parts of radix astragali seu hedysari, 6 to 12 parts of herba cistanche, 4 to 8 parts of radix bupleuri, 6 to 12 parts of ramulus cinnamomi, 10 to 30 parts of caulis spatholobi, 10 to 15 parts of radix paeoniae alba, 6 to 12 parts of semen trigonellae and 10 to 40 parts of corn stigma. According to the traditional Chinese medicine composition disclosed by the invention, all the medicines are combined to achieve the effects of warming yang, tonifying qi, promoting blood circulation, inducing diuresis, warming and tonifying kidney yang in lower jiao and stirring qi in triple jiao.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency, blood stasis and water retention type and application thereof. BACKGROUND

[0002] Chronic heart failure (CHF) is the final destination of most vascular diseases, with high morbidity, high rehospitalization rate and high mortality. CHF not only threatens people's health, but also increases the economic burden in the field of public health. It is estimated that the medical expenses related to CHF treatment will increase by more than 200% in the next 20 years. For CHF, the current mainstream treatment of heart failure is mainly aimed at the renin-angiotensin-aldosterone system and the neuroendocrine system pathway. However, the results of many large-scale clinical studies are not optimistic, and most drugs cannot improve the rehospitalization rate of patients with heart failure or the all-cause mortality of cardiovascular disease. The latest European Society of Cardiology guidelines have advocated the application of "new four combinations" to optimize the treatment plan, but there is a contradiction that patients cannot tolerate drug treatment. How to truly improve the benefits of patients and break through the difficulties of heart failure drug treatment is a major scientific problem that needs to be solved in the field of life medicine.

[0003] CHF is classified into "Zheng'eng", "asthma", "phlegm", "edema" and other categories in traditional Chinese medicine, and the main symptoms are palpitation, shortness of breath, fatigue, and edema of limbs, which are closely related to constitution, diet, rest, climate and other factors. The disease is located in the heart and is closely related to the kidneys, spleen, liver and lungs. Traditional Chinese medicine has unique advantages in the prevention and treatment of heart failure, and the combination of traditional Chinese and Western medicine in the diagnosis and treatment of heart failure can significantly improve the symptoms and signs of patients and improve the quality of life. At present, the main reference for clinical treatment is the TCM syndrome differentiation type in "Guidelines for the Diagnosis and Treatment of Chronic Heart Failure in Traditional Chinese Medicine (2022)". Traditional Chinese medicine theory believes that this disease is a deficiency in the root and excess in the branch. The deficiency in the root is mainly qi (yang) deficiency, and the excess in the branch is mainly blood stasis and phlegm. The main treatment principles are warming yang and benefiting qi, promoting blood circulation and reducing water.

[0004] The patent application with the publication number CN106822785A discloses a traditional Chinese medicine composition for treating chronic heart failure, a preparation method and application. The traditional Chinese medicine composition is made of the following raw materials: 7.5-75 parts of Poria cocos; 5-50 parts of Rhizoma Sparganii; 5-60 parts of Astragalus; 5-60 parts of Semen Lepidii; 5-50 parts of Ophiopogon japonicus; and 5-50 parts of Curcuma zedoary. The Astragalus in the embodiment of the present application benefits qi and reduces water, and the Semen Lepidii reduces lung water. They are the monarch drugs. Poria cocos and Ophiopogon japonicus benefit qi and reduce water, and they are the ministerial drugs. Rhizoma Sparganii and Curcuma zedoary promote blood circulation and remove blood stasis. The traditional Chinese medicine composition has the advantages of benefiting qi and reducing water, reducing lung water, benefiting qi and reducing water, nourishing yin and reducing water, promoting blood circulation and removing blood stasis, and the like. The traditional Chinese medicine composition can effectively treat chronic heart failure.

[0005] The patent application with the publication number CN115282219A discloses a traditional Chinese medicine composition for treating chronic heart failure, a preparation method and application thereof. The traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 10-30 parts of guizhi, 10-30 parts of zhuling, 10-30 parts of fuling, 10-30 parts of zexie, 10-30 parts of baizhu, 10-30 parts of mudanpi, 10-30 parts of taoren and 10-30 parts of shao yao. The traditional Chinese medicine composition has the effects of warming heart yang, promoting blood circulation and removing water, and is used for treating chronic heart failure of yang deficiency, blood stasis and water retention type, and has the effects of improving heart function and improving the quality of life of patients.

[0006] The patent application with the publication number CN113559223A discloses a traditional Chinese medicine compound composition for treating chronic heart failure, which comprises the following components: 20-60 parts of tingshengzi, 20-60 parts of da zao, 10-30 parts of e zhu, 10-30 parts of puhuang, 30-90 parts of shenghuangqi, 20-60 parts of danshen, 30-90 parts of hongjingtian, 10-30 parts of lulu tong, 20-60 parts of cheqiancao, 10-30 parts of fuling, 20-60 parts of chaobaizhu, 20-60 parts of yuzhu, 10-30 parts of guizhi and 10-30 parts of chushizi. The traditional Chinese medicine compound composition for treating chronic heart failure has the effects of purging lung water, tonifying qi and spleen, warming yang and removing blood stasis, can significantly improve the clinical symptoms of heart failure patients, improve the heart function classification and reduce the plasma B-type natriuretic peptide and other heart failure indicators, and has small long-term toxicity and safe and reliable drug safety.

[0007] The traditional Chinese medicine composition disclosed in the above patent application has a large number of medicinal ingredients, which increases the preparation process and is relatively complicated. Therefore, it is necessary to prepare a traditional Chinese medicine composition for treating chronic heart failure, which has obvious effects and moderate medicinal ingredients. However, there is no report on the traditional Chinese medicine composition for treating chronic heart failure according to the present application. SUMMARY

[0008] The purpose of the present application is to provide a traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency, blood stasis and water retention type.

[0009] Another purpose of the present application is to provide the use of the traditional Chinese medicine composition in the preparation of a drug for treating chronic heart failure of yang deficiency, blood stasis and water retention type.

[0010] In order to achieve the above purposes, the technical solutions adopted by the present application are as follows:

[0011] In the first aspect of the present application, a traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency, blood stasis and water retention type is provided, which is prepared from the following components in parts by weight:

[0012] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0013] More preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0014] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0015] Most preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0016] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0017] Most preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0018] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0019] Most preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0020] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0021] Most preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0022] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0023] Most preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0024] Corn Silk 10~40 parts, Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Radix Bupleuri 5~7 parts, Ramulus Cinnamomi 6~9 parts, Spatholobi Caulis 15~30 parts, Radix Paeoniae Alba 12~15 parts, Trigonella 8~10 parts.

[0025] Most preferably, the traditional Chinese medicine composition is made of the following components in parts by weight:

[0026] Xianlingpi 9 parts, Huangqi 12 parts, Cijilong 9 parts, Chaihu 6 parts, Guizhi 6 parts, Jixueteng 15 parts, Baishao 12 parts, Hulubo 9 parts, Corn silk 15 parts.

[0027] Most preferably, the traditional Chinese medicine composition is made from the following components in parts by weight:

[0028] Xianlingpi 12 parts, Huangqi 15 parts, Cijilong 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Hulubo 9 parts, Corn silk 30 parts.

[0029] Most preferably, the traditional Chinese medicine composition is made from the following components in parts by weight:

[0030] Xianlingpi 9 parts, Huangqi 30 parts, Cijilong 12 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 15 parts, Baishao 12 parts, Hulubo 9 parts, Corn silk 30 parts.

[0031] Most preferably, the traditional Chinese medicine composition is made from the following components in parts by weight:

[0032] Xianlingpi 9 parts, Huangqi 15 parts, Cijilong 12 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Hulubo 9 parts, Corn silk 15 parts.

[0033] Most preferably, the traditional Chinese medicine composition is made from the following components in parts by weight:

[0034] Xianlingpi 9 parts, Huangqi 15 parts, Cijilong 9 parts, Chaihu 6 parts, Guizhi 6 parts, Jixueteng 30 parts, Baishao 15 parts, Hulubo 9 parts, Corn silk 30 parts.

[0035] Most preferably, the traditional Chinese medicine composition is made from the following components in parts by weight:

[0036] Xianlingpi 9 parts, Huangqi 15 parts, Cijilong 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 15 parts, Baishao 12 parts, Hulubo 9 parts, Corn silk 30 parts.

[0037] In a second aspect of the present application, the application provides a use of the traditional Chinese medicine composition in the preparation of a medicine for treating chronic heart failure of yang deficiency and blood stasis and water retention type.

[0038] In a third aspect of the present application, a pharmaceutical preparation is provided, which is made from the traditional Chinese medicine composition and pharmaceutically acceptable adjuvants.

[0039] The dosage form of the pharmaceutical preparation is water decoction, granules, tablets, capsules, oral liquid, mixture, syrup.

[0040] In a fourth aspect of the present application, the application provides a use of the pharmaceutical preparation in the preparation of a medicine for treating chronic heart failure of yang deficiency and blood stasis and water retention type.

[0041] In the traditional Chinese medicine composition of the present application: Xianlingpi warms and tonifies kidney yang, and restrains kidney water; Huangqi is good at tonifying and ascending qi, tonifying the qi in the chest, Xianlingpi and Huangqi are the monarch herbs; Cogongrass enters the kidney channel, and absorbs kidney qi, and strengthens the kidney tonifying effect of Xianlingpi; Chaihu helps Huangqi to ascend yang and lift depression; Jiuxueteng activates blood and resolves stasis, and supplements blood and activates collaterals; Baishao is acid, sweet, and yin, Cogongrass, Chaihu, Jiuxueteng, and Baishao are the minister herbs; Guizhi is pungent, sweet, and warm, and can warm yang and transform qi; Huluba warms the kidney and assists yang with Xianlingpi and Cogongrass, and has the effect of descending qi, and the bitter and warm herbs enter the kidney, and assist Xianlingpi and Cogongrass to dry dampness and regulate the kidney; Corn silk diureses and reduces swelling, and guides water and dampness downward. Guizhi, Huluba, and Corn silk are the auxiliary herbs. The traditional Chinese medicine composition of the present application is in accordance with the combination of monarch, minister, auxiliary, and guide, and the combined use of the various herbs achieves the effects of warming yang and tonifying qi, activating blood and benefiting water, and warming and tonifying lower jiao kidney yang, and mediating the function of qi movement of triple energizer.

[0042] The nature, taste, meridian, and efficacy and indications of the traditional Chinese medicine raw materials in the present application are as follows:

[0043] Xianlingpi: nature, taste, and meridian: pungent, sweet, and warm; meridian: liver and kidney; efficacy: tonifying kidney yang, strengthening tendons and bones, and dispelling wind and dampness; indications: for kidney yang deficiency, impotence and spermatorrhea, flaccid tendons and bones, and wind-damp bi-syndrome and numbness and spasm.

[0044] Huangqi: nature, taste, and meridian: sweet and slightly warm; meridian: spleen and lung; efficacy: tonifying qi and ascending yang, benefiting defense and consolidating the exterior, benefiting water and reducing swelling, and promoting toxin elimination and muscle regeneration; indications: for qi deficiency and debilitation, poor appetite and loose stool, middle qi collapse, chronic diarrhea and prolapse, hematochezia and metrorrhagia, exterior deficiency and spontaneous sweating, qi deficiency and edema, and ulcer and chronic sore.

[0045] Cogongrass: nature, taste, and meridian: sweet and salty, and warm; meridian: kidney and large intestine; efficacy: tonifying kidney yang, benefiting essence and blood, and moistening the intestines and relieving constipation; indications: for kidney yang deficiency, essence and blood deficiency, impotence and infertility, lumbago and soreness of knees and waist, and weakness of tendons and bones, and dry intestines and constipation.

[0046] Chaihu: nature, taste, and meridian: pungent and sweet, and warm; meridian: heart, lung, and bladder; efficacy: inducing perspiration and relieving the exterior, warming and unblocking meridians, assisting yang and transforming qi, and descending and regulating qi; indications: for wind-cold invasion, cold pain in the abdomen, blood stasis and amenorrhea, joint pain, phlegm-dampness, edema, palpitation, and mania.

[0047] Guizhi: nature, taste, and meridian: pungent and sweet, and warm; meridian: heart, lung, and bladder; efficacy: inducing perspiration and relieving the exterior, warming and unblocking meridians, assisting yang and transforming qi, and descending and regulating qi; indications: for wind-cold invasion, cold pain in the abdomen, blood stasis and amenorrhea, joint pain, phlegm-dampness, edema, palpitation, and mania.

[0048] Jiuxueteng: nature, taste, and meridian: bitter and sweet, and warm; meridian: liver and kidney; efficacy: activating blood and tonifying blood, regulating menstruation and relieving pain, and relaxing tendons and dredging collaterals; indications: for irregular menstruation, dysmenorrhea, numbness and paralysis, wind-damp bi-syndrome, and blood deficiency and emaciation.

[0049] White peony root: nature and taste meridian: bitter, sour, cold; liver, spleen meridian. Function: nourishing blood and regulating menstruation, astringe Yin and stop sweating, softening the liver and relieving pain, calming liver yang. Indications: for blood deficiency, irregular menstruation, sweating, night sweat, hypochondriac pain, abdominal pain, limb spasm, headache and dizziness.

[0050] Fenugreek: nature and taste meridian: bitter, warm; kidney meridian. Function: warm kidney and assist yang, dispel cold and relieve pain. Indications: for kidney yang deficiency, lower cold, cold pain in the lower abdomen, cold abdominal pain, cold and wet feet.

[0051] Corn silk: nature and taste meridian: sweet, flat; bladder, liver, gallbladder meridian. Function: water and swelling, wet and yellow. Indications: for edema, oliguria, damp yellow, dizziness, red eyes, milk obstruction, nasal catarrh, mastitis.

[0052] Due to the adoption of the above technical scheme, the present application has the following advantages and beneficial effects:

[0053] The traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water drinking type provided by the present application has the advantages of treating both the symptoms and the root cause: Xianlingpi, cistanche and fenugreek in the prescription warm and tonify kidney yang to treat the root cause; astragalus and bupleurum ascend and lift the large qi in the chest; caesalpinia and white peony root promote blood circulation and nourish the nutrient QI; cassia twig and corn silk transform qi and drain water to treat the symptoms, realizing the integration of warming yang, ascending and descending, promoting blood circulation and draining water, treating both the symptoms and the root cause.

[0054] The traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water drinking type provided by the present application has the advantages of ascending yang and descending turbidity: astragalus and bupleurum ascend and lift the large qi in the chest; fenugreek and corn silk descend downward; cassia twig is acrid and sweet, which transforms yang. The whole prescription ascends clear yang and descends turbid yin, restoring the function of Sanjiao.

[0055] The traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water drinking type provided by the present application has the advantages of warming without dryness and purging without damage: most of the kidney warming drugs are dry, which can easily assist fire to damage yin if taken for a long time; the present application uses white peony root, caesalpinia and corn silk to astringe yin, nourish blood and moisten collaterals, which can not only prevent the dryness of Xianlingpi and fenugreek, but also prevent the damage of diuresis to body fluid, realizing the integration of warming yang without damaging yin and draining water without damaging the normal body functions.

[0056] The traditional Chinese medicine composition provided by the present application can be used as a medicine for treating chronic heart failure of yang deficiency and blood stasis and water drinking type. DETAILED DESCRIPTION

[0057] In order to more clearly illustrate the present application, the present application will be further described below in combination with preferred embodiments. Those skilled in the art should understand that the specific description below is illustrative rather than limiting, and should not limit the protection scope of the present application.

[0058] Example 1

[0059] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water drinking type:

[0060] Xianlingpi 9g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 30g, Baishao 12g, Huluba 9g, Yushu 30g.

[0061] Example 2

[0062] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0063] Xianlingpi 12g, Huangqi 12g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 15g, Baishao 12g, Huluba 9g, Yushu 30g.

[0064] Example 3

[0065] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0066] Xianlingpi 9g, Huangqi 30g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 30g, Baishao 12g, Huluba 9g, Yushu 30g.

[0067] Example 4

[0068] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0069] Xianlingpi 9g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 6g, Jixueteng 30g, Baishao 12g, Huluba 9g, Yushu 30g.

[0070] Example 5

[0071] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0072] Xianlingpi 9g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 30g, Baishao 12g, Huluba 9g, Yushu 15g.

[0073] Example 6

[0074] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0075] Xianlingpi 9g, Huangqi 12g, Cijilong 9g, Chaihu 6g, Guizhi 6g, Jixueteng 15g, Baishao 12g, Huluba 9g, Yushu 15g.

[0076] Example 7

[0077] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0078] Xianlingpi 12g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 30g, Baishao 12g, Huluba 9g, Simuxu 30g.

[0079] Example 8

[0080] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0081] Xianlingpi 9g, Huangqi 30g, Cijilong 12g, Chaihu 6g, Guizhi 9g, Jixueteng 15g, Baishao 12g, Huluba 9g, Simuxu 30g.

[0082] Example 9

[0083] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0084] Xianlingpi 9g, Huangqi 15g, Cijilong 12g, Chaihu 6g, Guizhi 9g, Jixueteng 30g, Baishao 12g, Huluba 9g, Simuxu 15g.

[0085] Example 10

[0086] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0087] Xianlingpi 9g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 6g, Jixueteng 30g, Baishao 15g, Huluba 9g, Simuxu 30g.

[0088] Example 11

[0089] A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type:

[0090] Xianlingpi 9g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 15g, Baishao 12g, Huluba 9g, Simuxu 30g.

[0091] Example 12

[0092] Clinical trial

[0093] 1 Research data

[0094] 1.1 General information

[0095] 100 patients with chronic heart failure with syndrome of yang deficiency and blood stasis and water retention were treated in the outpatient and inpatient departments of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine from July 2024 to July 2025, with a total research time of 2 months. In the test group, there were 50 patients, including 29 males and 21 females, with an average age of 68.40±13.21 years old. There were 12 cases of heart function II, 32 cases of III, and 4 cases of IV. There were 16 cases of heart failure with reduced ejection fraction (HFrEF), 18 cases of heart failure with mildly reduced ejection fraction (HFmrEF), and 12 cases of heart failure with preserved ejection fraction (HFpEF). In the control group, there were 50 patients, including 30 males and 20 females, with an average age of 68.22±12.79 years old. There were 14 cases of heart function II, 31 cases of III, and 5 cases of IV. There were 17 cases of heart failure with reduced ejection fraction (HFrEF), 17 cases of heart failure with mildly reduced ejection fraction (HFmrEF), and 16 cases of heart failure with preserved ejection fraction (HFpEF). There was no significant difference in gender, age, and disease duration between the test group and the control group (P>0.05).

[0096] 1.2 Chinese diagnostic criteria

[0097] According to the Chinese Yang deficiency and blood stasis syndrome diagnostic criteria in 'Guidelines for the Diagnosis and Treatment of Chronic Heart Failure (2022)'.

[0098] (1) Main symptoms: shortness of breath / wheezing, fatigue, palpitations.

[0099] (2) Secondary symptoms: ① Fear of cold and (or) preference for warmth; ② Stomach / abdomen / waist / limbs have a cold feeling; ③ Body feels cold, accompanied by sweating; ④ Face or lips are purple.

[0100] (3) Associated symptoms: cough / expectoration, chest fullness / abdominal distension, facial edema / edema, difficulty urinating.

[0101] (4) Tongue and pulse: purple tongue (or with blood stasis spots, blood stasis points or tortuous sublingual vessels), tongue body is large or has tooth marks; slippery or greasy tongue coating; weak, slow, and weak pulse; slippery pulse.

[0102] Note: With 2 main symptoms, 2 secondary symptoms, and tongue and pulse, yang deficiency and blood stasis syndrome can be diagnosed. With 1 associated symptom and tongue and pulse, water retention syndrome can be diagnosed.

[0103] 1.3 Western diagnostic criteria

[0104] According to the diagnostic criteria of "Chinese Heart Failure Diagnosis and Treatment Guidelines 2024": It belongs to chronic stable heart failure patients in heart failure stage C (clinical heart failure stage). That is, patients have organic heart disease, and have symptoms and / or signs of heart failure in the past or present. Clinical manifestations include patients with organic heart disease with decreased exercise tolerance (dyspnea, fatigue and fluid retention).

[0105] 1.4 Inclusion criteria

[0106] (1) Meet the diagnostic criteria for chronic heart failure and the diagnostic criteria for TCM yang deficiency and blood stasis and water retention syndrome;

[0107] (2) Age 18-80 years old, gender unrestricted;

[0108] (3) The patient's basic information is complete, can adhere to medication, and has follow-up conditions;

[0109] (4) Sign the informed consent form.

[0110] 1.5 Exclusion criteria

[0111] (1) Combined with restrictive (infiltrative) cardiomyopathy, congenital heart disease;

[0112] (2) Acute coronary syndrome;

[0113] (3) History of stent placement, coronary artery bypass surgery within 90 days, implanted permanent pacemaker, implanted defibrillator;

[0114] (4) Severe liver and kidney dysfunction;

[0115] (5) Combined with malignant tumor, hematopoietic system disease, acute infectious disease;

[0116] (6) Pregnant or lactating women;

[0117] (7) Allergic to related traditional Chinese medicines in the traditional Chinese medicine composition.

[0118] 1.6 Treatment method

[0119] (1) The control group uses western medicine standard treatment, and the recommended drugs and comprehensive management of "Chinese Heart Failure Diagnosis and Treatment Guidelines 2024" are used for treatment.

[0120] (2) The test group is given the traditional Chinese medicine composition of the present application example 11 on the basis of western medicine standard treatment, concentrated decoction, water decoction, 200ml per bag, 1 bag per day, every 4 weeks as a course of treatment, a total of 2 courses.

[0121] 1.7 Observation index

[0122] During the medication, adverse reactions of the drugs were evaluated according to the Clinical Adverse Drug Reactions Encyclopedia, the changes of heart rate and blood pressure were closely monitored, liver and kidney functions and blood routine tests were given, and the occurrence of adverse reactions of the drugs was recorded in detail and symptomatic treatment was given in time. The changes of New York Heart Association (NYHA) cardiac function classification, left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-proBNP) level, six-minute walk test (6MWT) and Minnesota Living with Heart Failure Quality of Life Scale (MLHFQ) score before and after 8 weeks of treatment were observed.

[0123] 1.8 Clinical efficacy determination

[0124] According to the NYHA grading method, the therapeutic effect of heart function was evaluated. (1) Marked effect: the heart function was basically controlled or the heart function was improved by 2 levels or more. (2) Effectiveness: the heart function was improved by 1 level, but less than 2 levels. (3) Ineffectiveness: the heart function was improved by less than 1 level. (4) Worsening: the heart function was worsened by 1 level or more.

[0125] 1.9 Statistical processing

[0126] In this study, R language was used for data processing. When the measurement data met the normal distribution and homogeneity of variance, t test was used. When the measurement data did not meet the normal distribution (or the variance was not uniform), non-parametric test was used. The grade data was described by grade score, and the Kruskal-Wallis rank sum test was used for comparison between groups. P<0.05 was considered to have statistical significance.

[0127] 2 Results

[0128] 2.1 Comparison of clinical total efficacy of patients in two groups

[0129] The clinical total effective rate of the test group was 86.00%, and the clinical total effective rate of the control group was 60.00%. The difference between the two groups was statistically significant (P<0.05), and the data is shown in Table 1:

[0130] Table 1 Comparison of clinical efficacy of patients in two groups (cases (%))

[0131]

[0132] Note: compared with the control group, #P<0.05.

[0133] The test group had a marked effect of 10% and an effectiveness of 76%. The control group had a marked effect of only 4% and an effectiveness of 56%. It is suggested that the use of the traditional Chinese medicine composition in the present application is superior to simple western medicine in terms of "improving 2 levels" or "improving 1 level" of heart function, and can improve the clinical total efficacy of chronic heart failure.

[0134] 2.2 Comparison of NYHA cardiac function classification of patients in two groups before and after treatment

[0135] There was no statistically significant difference in NYHA classification of cardiac function between the two groups before treatment (P>0.05). After treatment, the cardiac function of the patients in the test group improved significantly, and the NYHA classification of cardiac function of the test group was better than that of the control group, with statistically significant difference (P<0.05). The results are shown in Table 2.

[0136] Table 2 Comparison of NYHA classification of cardiac function of the patients in the two groups before and after treatment

[0137]

[0138] The NYHA classification of the two groups was consistent before treatment (P>0.05). After treatment, the number of patients with III-IV grade in the test group decreased from 36 to 9, and 8 patients were converted to NYHA I grade. After treatment, the number of patients with III-IV grade in the control group decreased from 36 to 19, and 3 patients were converted to NYHA I grade, which was significantly more than that of the control group. It is suggested that the use of the traditional Chinese medicine composition of the application can significantly improve the NYHA classification of cardiac function of patients with chronic heart failure.

[0139] 2.3 Comparison of LVEF of the two groups before and after treatment

[0140] Before treatment, there was no statistically significant difference in LVEF between the two groups (P>0.05). After treatment, the LVEF of the patients with non-preserved ejection fraction heart failure (HFrEF+HFmrEF) in the test group improved significantly (P<0.05), and there was no statistically significant difference in the control group (P>0.05). There was no statistically significant difference in LVEF of the patients with HFpEF before and after treatment (P>0.05), and there was no statistically significant difference between the two groups (P>0.05). The results are shown in Table 3.

[0141] Table 3 Comparison of LVEF of the two groups before and after treatment (%, )

[0142]

[0143] Note: *P<0.05 compared with before treatment; #P<0.05 compared with the control group.

[0144] There was no difference in LVEF baseline between the two groups before treatment; after treatment, the LVEF of the patients with HFrEF+HFmrEF in the test group increased from (38.26±6.98)% to (44.35±7.56)%, with a net increase of 6.1% (P<0.05), while the control group only increased by 0.7% and had no statistical significance, indicating that the use of the traditional Chinese medicine composition of the application on the basis of western medicine can significantly restore myocardial contractility and reverse ventricular remodeling.

[0145] 2.4 Comparison of NT-proBNP of the two groups before and after treatment

[0146] Before treatment, the difference in NT-proBNP between the two groups was not statistically significant (P>0.05). After treatment, the NT-proBNP of the two groups decreased significantly, and the decrease in the test group was more obvious (P<0.05). There were 39 cases in the test group whose NT-proBNP decreased by more than 30% before and after treatment, and there were 26 cases in the control group whose NT-proBNP decreased by more than 30% before and after treatment. The results are shown in Table 4:

[0147] Table 4 Comparison of NT-proBNP between the two groups before and after treatment (pg / ml, )

[0148]

[0149] Note: Compared with before treatment, *P<0.05; compared with the control group, #P<0.05.

[0150] Before treatment, the NT-proBNP of the two groups was at the same baseline. After treatment, the median value of the test group decreased from 2668 pg / ml to 497 pg / ml, and there were 39 cases whose NT-proBNP decreased by more than 30%, which was significantly better than the 26 cases in the control group (P<0.05). It is suggested that after using the traditional Chinese medicine composition of the present application, the NT-proBNP level can be significantly reduced, the overactivation of neuroendocrine can be inhibited, and the heart function can be improved.

[0151] 2.5 Comparison of 6MWT between the two groups before and after treatment

[0152] Before treatment, there was no statistically significant difference in 6MWT between the two groups (P>0.05). After treatment, the 6MWT of the two groups increased significantly, and the increase in the test group was more obvious (P<0.05). There were 6 patients in the test group whose 6MWT was greater than 450m after treatment, and there were 2 patients in the control group whose 6MWT was greater than 450m after treatment. The results are shown in Table 5:

[0153] Table 5 Comparison of 6MWT between the two groups before and after treatment (m, )

[0154]

[0155] Note: Compared with before treatment, *P<0.05; compared with the control group, #P<0.05.

[0156] Before treatment, there was no difference in six-minute walking distance between the two groups. After treatment, the test group increased from 259 meters to 336 meters, with an increase of 77 meters, which was significantly better than the 47 meters of the control group (P<0.05), and 6 patients in the test group could walk 450 meters, while only 2 patients in the control group could walk 450 meters. Six-minute walking distance directly reflects exercise tolerance and daily activity ability. After using the traditional Chinese medicine composition of the present application, the six-minute walking distance of chronic heart failure patients can be significantly increased, and self-care can be restored. The efficacy is better than that of simple western medicine.

[0157] 2.6 Comparison of MLHFQ of two groups before and after treatment

[0158] Before treatment, there was no statistically significant difference in the comparison of MLHFQ of patients in two groups (P>0.05). After treatment, the MLHFQ of two groups was significantly reduced, and the increase of the test group was more obvious (P<0.05). The results are shown in Table 6:

[0159] Table 6 Comparison of MLHFQ of two groups before and after treatment (points, )

[0160]

[0161] Note: *P<0.05 compared with before treatment; #P<0.05 compared with the control group.

[0162] There was no difference in MLHFQ between two groups before treatment. After 8 weeks of treatment, the test group decreased from 53.3 points to 38.9 points, with a decrease of 14.4 points, which was significantly greater than 6.6 points of the control group (P<0.05). It is found that the use of the traditional Chinese medicine composition of the present application can significantly improve the quality of life and daily activity ability of patients.

[0163] 2.7 Safety results of patients in two groups before and after treatment

[0164] There were no serious adverse reactions in patients in two groups before and after treatment through dynamic observation of liver and kidney function, blood routine and the like.

[0165] Example 13

[0166] Wu, male, 61 years old.

[0167] First visit: November 19, 2024.

[0168] Complaint: recurrent chest tightness and shortness of breath for more than 1 month.

[0169] Present illness history: The patient had chest tightness and shortness of breath after "cold" one month ago, accompanied by palpitations. He was diagnosed with "heart failure-dilated cardiomyopathy" after examination in a hospital in Shanghai and was treated with oral "sacubitril / valsartan 100 mg bid + dapagliflozin 10 mg qd + metoprolol succinate 23.75 mg qd + spironolactone 20 mg qd". For further treatment in combination with traditional Chinese and Western medicine, he visited the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine. Current symptoms: The patient has frequent chest tightness and shortness of breath after slight activity, accompanied by palpitations, fatigue, sweating, cold limbs, slight edema of both lower extremities, normal appetite, cold pain in the epigastric region, regular bowel movements, restless sleep, light sleep, 3-4 nocturia, dark red tongue with thin white fur, and slow pulse.

[0170] Past history: Deny hypertension, diabetes, coronary heart disease history. Deny smoking history, drink alcohol for more than 30 years, 50ml of yellow wine per day.

[0171] Physical examination: blood pressure: 95 / 60mmHg, heart rate 113 times / min, arrhythmia, no dry and wet rales were heard in both lungs, and there was slight edema in both lower limbs.

[0172] Auxiliary examination: ECG: sinus tachycardia, ventricular trigeminy, T wave changes. Echocardiography: whole heart enlargement, diffuse segmental motion of left ventricular wall decreased, left ventricular systolic and diastolic function decreased (LVEF 35%), mild mitral regurgitation, mild pulmonary artery pressure increased. NT-proBNP 2640pg / ml. Myocardial enzymes, blood routine, blood biochemistry, coagulation and other indicators were normal. No obvious stenosis was found in coronary CTA.

[0173] Diagnosis:

[0174] TCM diagnosis: heart failure-disease of yang deficiency and blood stasis and water retention.

[0175] Western medicine diagnosis: 1. Heart failure-dilated cardiomyopathy; 2. Arrhythmia-ventricular premature beat.

[0176] Treatment: warming yang and benefiting qi, promoting blood circulation and removing water.

[0177] Prescription: Xianlingpi 9g, Huangqi 15g, Ruangongrong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 15g, Baishao 12g, Hulubo 9g, Yushu 30g, 14 doses, one dose per day, concentrated decoction in the morning and evening.

[0178] Reexamination on December 3, 2024

[0179] After taking medicine, the patient's chest tightness, shortness of breath, cold limbs, and palpitation were greatly reduced, and the fatigue was improved. Naka, abdominal cold pain was relieved, stool was adjusted, sleep was gradually calm, and night urine was reduced to 2-3 times. Dark red tongue with thin white fur, pulse was deep and fine. Blood pressure 100 / 65mmHg, heart rate 96 times / min, arrhythmia, no dry and wet rales were heard in both lungs, and there was no edema in both lower limbs. The prescription was not changed.

[0180] Prescription: Xianlingpi 9g, Huangqi 15g, Ruangongrong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 15g, Baishao 12g, Hulubo 9g, Yushu 30g, 49 doses, one dose per day, concentrated decoction in the morning and evening.

[0181] Reexamination on January 21, 2025

[0182] After treatment, the patient's chest tightness and shortness of breath have improved, and there are no symptoms such as palpitations, cold pain in the abdomen, cold limbs, and other symptoms. The patient's energy is significantly improved. The patient can eat normally, and the stool is regular. The patient sleeps well at night, and the night urination is reduced to once. The tongue is pale and dark with thin white fur, and the pulse is thin. The blood pressure is 110 / 72 mmHg, the heart rate is 82 times / min, the rhythm is regular, and there is no dry or wet rale in the lungs. The patient's lower limbs are not edematous.

[0183] Recheck ECG: sinus rhythm, no premature ventricular contractions. Echocardiography: left heart enlargement (left ventricle), left ventricular systolic and diastolic function decreased (LVEF 48%), mild mitral regurgitation. NT-proBNP 504.9 pg / ml. The rest of the indicators such as myocardial enzymes, blood routine, blood biochemistry, and coagulation are normal. Stop taking Chinese medicine.

[0184] 2025 May 20 recheck

[0185] The patient has no chest tightness, shortness of breath, palpitations, cold pain in the abdomen, cold limbs, and other discomforts. The patient has no night urination and can perform normal physical activities. The tongue is pale and dark with thin white fur, and the pulse is thin. The blood pressure is 115 / 75 mmHg, the heart rate is 75 times / min, the rhythm is regular, and there is no dry or wet rale in the lungs. The patient's lower limbs are not edematous. Recheck ECG: sinus rhythm, normal ECG. Echocardiography: left heart enlargement (left ventricle), left ventricular diastolic function decreased, mild mitral regurgitation, LVEF increased to 52%. NT-proBNP decreased to 117.3 pg / ml. The rest of the indicators such as myocardial enzymes, blood routine, blood biochemistry, and coagulation are normal.

[0186] Example 14

[0187] Gu Meng, male, 57 years old.

[0188] First visit: May 28, 2025.

[0189] Complaint: recurrent shortness of breath, fatigue, and palpitations for more than 1 year, aggravated for 1 month.

[0190] Present illness history: The patient underwent coronary stent implantation for acute myocardial infarction in April 2024 and radiofrequency ablation combined with left atrial appendage occlusion for atrial fibrillation in May 2025. After the operation, the patient had symptoms of shortness of breath, fatigue, and edema of both lower extremities. The patient took "sacubitril / valsartan 100 mg bid + dapagliflozin 10 mg qd + aspirin 100 mg qd + atorvastatin 20 mg qn + ezetimibe 10 mg qd + bisoprolol fumarate 2.5 mg qd + spironolactone 20 mg qd" treatment, and the symptoms were slightly relieved. The patient has experienced shortness of breath, fatigue, palpitations, cold limbs, and cold limbs, and has experienced sweating, edema of both lower extremities (++), for the past month. The patient can eat normally, and the stool is regular. The patient sleeps well at night, the tongue is pale and dark with white and slightly greasy fur, and the pulse is thin.

[0191] Past history: hypertension for more than 20 years, the highest blood pressure 210 / 110 mmHg, now the blood pressure control is acceptable. Past history of hyperlipidemia. Smoking history for more than 30 years, quit smoking for 1 year, denied alcohol preference.

[0192] Physical examination: blood pressure: 125 / 75 mmHg, heart rate 82 times / min, regular, no dry and wet rales were heard in both lungs, bilateral lower extremity edema (++). 6-minute walk 225 meters.

[0193] Auxiliary examination: ECG: sinus rhythm, ST-T segment changes. Echocardiography: left heart enlargement, left ventricular systolic activity is not coordinated (LVEF 43%), mild to moderate mitral regurgitation, moderate increase in pulmonary artery pressure. NT-proBNP 2528 pg / ml. Creatinine 114 umol / L, myocardial enzymes and blood routine, blood biochemistry, coagulation and other indicators are normal.

[0194] Diagnosis:

[0195] TCM diagnosis: heart failure - yang deficiency and blood stasis and water retention.

[0196] Western medicine diagnosis: 1. Heart failure; 2. Coronary atherosclerotic heart disease - old myocardial infarction, post-stent implantation state; 3. Hyperlipidemia; 4. Renal insufficiency.

[0197] Treatment: warming yang and benefiting qi, promoting blood circulation and removing water.

[0198] Prescription: Xianlingpi 9g, Huangqi 15g, Cijilong 9g, Chaihu 6g, Guizhi 9g, Jixueteng 15g, Baishao 12g, Hulubo 9g, Shuchangsu 30g, 14 doses, one dose a day, concentrated decoction in the morning and evening.

[0199] Re-examination on June 11, 2025

[0200] After taking medicine, shortness of breath, fatigue, palpitation, fear of cold, and cold limbs were greatly reduced. The patient had normal appetite, regular bowel movements, and good sleep. The tongue was dark red with thin white fur, and the pulse was deep and fine. Blood pressure was 120 / 76 mmHg, heart rate was 78 times / min, regular, no dry and wet rales were heard in both lungs, and bilateral lower extremity edema was (+). The prescription was not changed, 42 doses, one dose a day, concentrated decoction in the morning and evening.

[0201] Re-examination on July 23, 2025

[0202] After taking medicine, shortness of breath, fatigue, palpitation, fear of cold, and cold limbs were greatly reduced. The patient had normal appetite, regular bowel movements, and good sleep. The tongue was dark red with thin white fur, and the pulse was deep and fine. Blood pressure was 120 / 76 mmHg, heart rate was 78 times / min, regular, no dry and wet rales were heard in both lungs, and bilateral lower extremity edema was (+). The prescription was not changed, 42 doses, one dose a day, concentrated decoction in the morning and evening.

[0203] Recheck ECG: sinus rhythm, ST-T segment changes. Echocardiography: left heart enlargement, left ventricular systolic activity is not coordinated (LVEF 52%), mild to moderate mitral regurgitation, pulmonary artery pressure moderately increased. NT-proBNP 1875 pg / ml. Creatinine 91 umol / L, myocardial enzymes and blood routine, blood biochemistry, coagulation and other indicators are normal.

[0204] Efficiency does not change the way, continue 98.

[0205] 2025 October 29 recheck

[0206] After taking medicine, symptoms such as shortness of breath, fatigue, palpitation, cold limbs and other symptoms, and profuse sweating were significantly reduced. Naka, stool regulation, night sleep. Dark red tongue, thin white fur, pulse is deep and fine. Blood pressure 122 / 68 mmHg, heart rate 76 times / min, rhythm, no dry and wet rales were heard in both lungs, and no edema was found in both lower limbs. 6-minute walk 461 meters. 5 days ago, climbing mountain aerobic exercise for 4 hours, no shortness of breath, palpitation symptoms, and activity after fatigue symptoms can be reduced.

[0207] Recheck ECG: sinus rhythm, ST-T segment changes. Echocardiography: left heart enlargement, left ventricular systolic activity is not coordinated (LVEF 53%), mild to moderate mitral regurgitation, pulmonary artery pressure moderately increased. NT-proBNP 1625 pg / ml. Creatinine 94 umol / L, myocardial enzymes and blood routine, blood biochemistry, coagulation and other indicators are normal.

[0208] The above only is the preferred embodiment of the present application, and does not limit the present application in any form, although the present application has been disclosed as above, however, it is not intended to limit the present application, any skilled person in the art within the scope of the present application technical solution, when can use the above-mentioned technical content of the prompt to make some changes or modification of equivalent changes of equivalent embodiments, but whatever is not out of the scope of the present application technical solution, according to the technical essence of the present application, the above embodiments of any simple modification, equivalent changes and modification, still belong to the scope of the present application.

Claims

1. A traditional Chinese medicine composition for preventing and treating chronic heart failure of yang deficiency and blood stasis and water retention type, characterized in that, is made from the following components in parts by weight: Xianlingpi 6~12 parts, Huangqi 10~30 parts, Cynomorium 6~12 parts, Chaihu 4~8 parts, Guizhi 6~12 parts, Jixueteng 10~30 parts, Baishao 10~15 parts, Huluba 6~12 parts, Corn silk 10~40 parts.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9~12 parts, Huangqi 12~30 parts, Cynomorium 9~12 parts, Chaihu 5~7 parts, Guizhi 6~9 parts, Jixueteng 15~30 parts, Baishao 12~15 parts, Huluba 8~10 parts, Corn silk 15~30 parts.

3. The traditional Chinese medicine composition according to claim 2, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 15 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 30 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 12 parts, Huangqi 12 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 15 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 30 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 30 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 30 parts.

4. The traditional Chinese medicine composition according to claim 2, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 15 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 6 parts, Jixueteng 30 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 30 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 15 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 15 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 12 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 6 parts, Jixueteng 15 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 15 parts.

5. The traditional Chinese medicine composition according to claim 2, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 12 parts, Huangqi 15 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 30 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 30 parts, Cynomorium 12 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 15 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 30 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 15 parts, Cynomorium 12 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 30 parts, Baishao 12 parts, Huluba 9 parts, Corn silk 15 parts.

6. The traditional Chinese medicine composition according to claim 2, characterized in that, The traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 15 parts, Cynomorium 9 parts, Chaihu 6 parts, Guizhi 6 parts, Jixueteng 30 parts, Baishao 15 parts, Huluba 9 parts, Corn silk 30 parts; Or, the traditional Chinese medicine composition is made from the following components in parts by weight: Xianlingpi 9 parts, Huangqi 15 parts, Cikongrong 9 parts, Chaihu 6 parts, Guizhi 9 parts, Jixueteng 15 parts, Baishao 12 parts, Hulubo 9 parts, Corn silk 30 parts.

7. Use of the traditional Chinese medicine composition of any one of claims 1 to 6 in the preparation of a medicament for treating chronic heart failure of yang deficiency and blood stasis and water retention type.

8. A pharmaceutical preparation, characterized by, is prepared from the traditional Chinese medicine composition of any one of claims 1 to 6 and pharmaceutically acceptable adjuvants.

9. The pharmaceutical preparation according to claim 8, characterized in that The dosage form of the pharmaceutical preparation is water decoction, granules, tablets, capsules, oral liquid, mixture, syrup.

10. Use of the pharmaceutical preparation of claim 8 or 9 in the preparation of a medicament for treating chronic heart failure of yang deficiency and blood stasis and water retention type.

Images